A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701)
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine: * People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day. * People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group, PA — Fayetteville, Arkansas
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Highlands Oncology Group, PA — Fayetteville, Arkansas
- Highlands Oncology Group, PA — Rogers, Arkansas
- Highlands Oncology Group, PA — Springdale, Arkansas
- Clinical and Translational Research Center (CTRC) — Aurora, Colorado
- UCHealth Sue Anschutz-Rodgers Eye Center — Aurora, Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- Brigham and Women's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Dana-Farber Cancer Institute - Chestnut Hill — Newton, Massachusetts
- Brigitte Harris Cancer Pavilion — Detroit, Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- Henry Ford Medical Center - Columbus — Novi, Michigan
- CT Scan and Echo Only: Henry Ford Medical Center-Plymouth — Plymouth, Michigan
- MSK Monmouth — Middletown, New Jersey
- MSK David H. Koch Center for Cancer Care — New York, New York
- Memorial Sloan Kettering Cancer Center 53rd street — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic Taussig Cancer Center Investigational Pharmacy — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.